Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification.~* Have HbA1c of 7.0% to 10.5%, inclusive, as assessed by the central laboratory.~* If on metformin, have been treated with stable doses of metformin for at least 3 months.~* Have a body mass index (BMI) ≥23 and \<50 kilograms per square meter.~Exclusion Criteria:~* Have type 1 diabetes (T1D).~* Have used any glucose-lowering medication other than metformin within 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past.~* Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke).~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial.~* Have had chronic or acute pancreatitis any time prior to study entry.~* Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation.~* Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry.~* Have any condition that is a contraindication for use of the GLP-1 RA class (per country-specific labels) at study entry or develop such condition between study entry and randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
- 1 mg Tirzepatide (Type: EXPERIMENTAL): 1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
- 1.5 mg Dulaglutide (Type: ACTIVE_COMPARATOR): 1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete